# Edwards Lifesciences (EW) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EW
## Company Profile
- Ticker: EW
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Cardio-Metabolic
## Stock Data
- Close: 89.9 USD
- Market cap: 50474628000 USD
- Last updated: 2026-09-04
## Business Overview
Edwards Lifesciences is a medical technology company best known for transcatheter heart valve therapies and critical care monitoring. The business is centered on structural heart innovation and procedure adoption.
## Why The Stock Is Moving

As of Sep 4, 2026, EW was little changed and closed at $89.90. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, Edwards is a global medtech company with strong exposure to cardiovascular procedures. It sits outside biotech and closer to high-end medical devices.

## Business Model

The company generates revenue through transcatheter valve systems, monitoring technologies, and related procedure-based products. Investors focus on procedure growth, product expansion, and how well the company can keep widening adoption in structural heart care.

## Landscape Position

Edwards is not biotech proper, but it occupies a premium position in healthcare innovation. It tends to move on device adoption and clinical uptake rather than on drug approvals or pipeline readouts.

## Future Catalysts

- Edwards Lifesciences is likely to be driven by TAVR demand, EVOQUE adoption in tricuspid therapy, and continued SAPIEN franchise strength. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2020-04-27 20:30 EST — [Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients](https://biopharmsignal.com/news/EW/edwards-hemosphere-platform-receives-expanded-use-indication-from-health-canada--1943ceb1) — Source: Edwards Lifesciences
- 2020-04-27 20:30 EST — [La plateforme HemoSphere d'Edwards reçoit une Indication élargie de la part de Santé Canada dans le traitement des patients atteints du COVID-19](https://biopharmsignal.com/news/EW/la-plateforme-hemosphere-d-edwards-re-oit-une-indication-largie-de-la-part-de-sa-0841b92c) — Source: Edwards Lifesciences